tbuckley/cabot-search huggingface dataset:
Retrospective study on the safety and efficacy of CART for patients with malignant ascites who received chemotherapy
Authors: Yoshimitsu Kobayashi, Joji Shimono, Takuma Takasaka, Taiki Kudo, Kazuhiro Tkahashi, Kohei Okada, Masayoshi Dazai, Susumu Sogabe, Hisashi Oda, Takuto Miyagishima
Journal: Annals of Oncology (2015)
13-cis-Retinoic Acid Plus Interferon- 2a in Recurrent Respiratory Papillomatosis
Authors: S. M. Lippman, D. T. Donovan, R. A. Frankenthaler, R. S. Weber, C. L. Earley, W. K. Hong, H. Goepfert
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article 13- cis -Retinoic Acid Plus Interferon-α2a in Recurrent Respiratory Papillomatosis Get access Scott M. Lippman, Scott M. Lippman (Departments of Thoracic/ Head and Neck Medical Oncology), The University of Texas M. D. Anderson Cancer CenterHouston Correspondence to : Scott M. Lippman, M.D., Associate Professor of Medicine, The University of Texas M. D. Anderson Cancer Center, Department of Thoracic/Head and Neck Medical Oncology, 1515 Holcombe Blvd.. Box 80, Houston, TX 77030. Search for other works by this author on: Oxford Academic PubMed Google Scholar Donald T. Donovan, Donald T. Donovan Baylor College of MedicineHouston, Tex Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert A. Frankenthaler, Robert A. Frankenthaler (Head and Neck Surgery), The University of Texas M. D. Anderson Cancer CenterHouston Search for other works by this author on: Oxford Academic PubMed Google Scholar Randal S. Weber, Randal S. Weber (Head and Neck Surgery), The University of Texas M. D. Anderson Cancer CenterHouston Search for other works by this author on: Oxford Academic PubMed Google Scholar Charles L. Earley, Charles L. Earley (Departments of Thoracic/ Head and Neck Medical Oncology), The University of Texas M. D. Anderson Cancer CenterHouston Search for other works by this author on: Oxford Academic PubMed Google Scholar Waun Ki Hong, Waun Ki Hong (Departments of Thoracic/ Head and Neck Medical Oncology), The University of Texas M. D. Anderson Cancer CenterHouston Search for other works by this author on: Oxford Academic PubMed Google Scholar Helmuth Goepfert Helmuth Goepfert (Head and Neck Surgery), The University of Texas M. D. Anderson Cancer CenterHouston Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 11, 1 June 1994, Pages 859–861, https://doi.org/10.1093/jnci/86.11.859 Published: 01 June 1994 Article history Received: 31 January 1994 Accepted: 14 March 1994 Published: 01 June 1994
Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced<i>EGFR</i>Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial
Authors: Amanda J. Redig, Daniel B. Costa, Myriam Taibi, David Boucher, Bruce E. Johnson, Pasi A. Jänne, David M. Jackman
Journal: JAMA Oncology (2016)

TrialTumor genotyping is standard-of-care for patients with advanced non-small-cell lung cancer (NSCLC), 1 but treatment decisions for patients with progressive disease increasingly depend on identifying the specific mechanism of acquired resistance. 2,3 To our knowledge, a comprehensive assessment of consent to undergo a repeated biopsy and logistical outcomes in patients receiving targeted therapy has not been prospectively evaluated in a single study; thus we performed a phase 2 prospective analysis of repeated biopsy in patients with advanced, tyrosine kinase inhibitor (TKI)-naïve, EGFR-mutant NSCLC treated with erlotinib until progression.
Serotype/serogroup-specific antibiotic non-susceptibility of invasive and non-invasive Streptococcus pneumoniae, Switzerland, 2004 to 2014
Authors: Christoph Hauser, Andreas Kronenberg, Aurélie Allemann, Kathrin Mühlemann, Markus Hilty
Journal: Eurosurveillance (2016)

Concurrent analysis of antibiotic resistance of colonising and invasive Streptococcus pneumoniae gives a more accurate picture than looking at either of them separately. Therefore, we analysed 2,129 non-invasive and 10,996 invasive pneumococcal isolates from Switzerland from 2004 to 2014, which spans the time before and after the introduction of the heptavalent (PCV7) and 13-valent (PCV13) conjugated pneumococcal polysaccharide vaccines. Serotype/serogroup information was linked with all antibiotic resistance profiles. During the study period, the proportion of non-susceptible non-invasive and invasive isolates significantly decreased for penicillin, ceftriaxone, erythromycin and trimethoprim/sulfamethoxazole (TMP-SMX). This was most apparent in non-invasive isolates from study subjects younger than five years (penicillin (p = 0.006), erythromycin (p = 0.01) and TMP-SMX (p = 0.002)). Resistant serotypes/serogroups included in PCV7 and/or PCV13 decreased and were replaced by non-PCV13 serotypes (6C and 15B/C). Serotype/serogroup-specific antibiotic resistance rates were comparable between invasive and non-invasive isolates. Adjusted odds ratios of serotype/serogroup-specific penicillin resistance were significantly higher in the west of Switzerland for serotype 6B (1.8; 95% confidence interval (CI): 1.4–4.8), 9V (3.4; 95% CI: 2.0–5.7), 14 (5.3; 95% CI: 3.8–7.5), 19A (2.2; 95% CI: 1.6–3.1) and 19F (3.1; 95% CI: 2.1–4.6), probably due to variations in the antibiotic consumption.
The validated sun exposure questionnaire: association of objective and subjective measures of sun exposure in a Danish population‐based sample
Authors: B. Køster, J. Søndergaard, J.B. Nielsen, M. Allen, A. Olsen, J. Bentzen
Journal: British Journal of Dermatology (2016)

Few questionnaires used in monitoring sun‐related behaviour have been tested for validity. We established the criteria validity of a questionnaire developed for monitoring population sun‐related behaviour. During May–August 2013, 664 Danes wore a personal electronic ultraviolet radiation (UVR) dosimeter for 1 week that measured their outdoor time and dose of erythemal UVR exposure. In the following week, they answered a questionnaire on their sun‐related behaviour in the measurement week. Outdoor time measured by dosimetry correlated strongly with both outdoor time and the developed exposure scale measured in the questionnaire. Exposure measured in standard erythema dose (SED) by dosimetry correlated strongly with the exposure scale. In a linear regression model of UVR (SED) received, 41% of the variation was explained by skin type, age, week of participation and exposure scale, with exposure scale as the main contributor. The weekly sunburn fraction correlated strongly with the number of ambient sun hours (r = 0·73, P < 0·001). This criteria‐validated questionnaire provides evidence of the exposure that the questionnaire aimed to measure. The evidence provided showed a strong link between the objectively measured behaviour and the behaviour measured by this survey construct. The questionnaire is the first validated tool to measure the UVR exposure in a national population‐based sample.
Comparing Two Multifraction Spine Radiotherapy Regimens: Are They Really Equivalent?
Authors: Daniel E. Spratt, Nicholas Szerlip
Journal: Journal of Clinical Oncology (2016)

an important radiotherapy question for patients with metastatic epidural spinal cord compression. The trial results nicely demonstrate the efficacy of two commonly used palliative radiotherapy regimensonimportantfunctionalandtumorcontrolend points (eg, motor function, ambulation, and local progression-free survival).
Percutaneous Left Atrial Appendage Suture Ligation Using the LARIAT Device in Patients With Atrial Fibrillation
Authors: Krzysztof Bartus, Frederick T. Han, Jacek Bednarek, Jacek Myc, Boguslaw Kapelak, Jerzy Sadowski, Jacek Lelakowski, Stanislaw Bartus, Steven J. Yakubov, Randall J. Lee
Journal: Journal of the American College of Cardiology (2012)
Rituximab As Second Line Treatment For Adult Immune Thrombocytopenia (ITP): A Multicentre, Randomized, Double Blind, Placebo-Controlled Study – The Ritp Study (NCT00344149)
Authors: Waleed Ghanima, Abderrahim Khelif, Neila Benromdhan, Anders Waage, Geir E. Tjonnfjord, Marc Michel, Darne Bernadette, Johannes Kahrs, Pål Andre Holme
Journal: Blood (2013)
P-068 Cetuximab in addition to oxaliplatin, fluorouracil and radiotherapy for patients with esophageal cancer treated without surgery
Authors: G. Alexandersson von Döbeln, G. Wagenius, E. Holtved, O. Hjortland Geir, M. Nilsson, L. Baeksgaard
Journal: Annals of Oncology (2016)
Fréquence et facteurs de risques de résection chirurgicale de polypes colorectaux: une étude de population
Authors: N Musquer
Journal: Endoscopy (2016)

A l’heure du développement de l’endoscopie interventionnelle, y a-t-il encore, et si oui pour quelles raisons, des patients adressés en première intention au chirurgien pour des adénomes colorectaux ? Ces 2 questions constituaient les objectifs principaux de cette étude rétrospective rennaise compilant l’ensemble des coloscopies réalisées entre 2002 et 2012 pour test Hemoccult positif dans le département d’Ile et Vilaine.
Pathways: A Road to Restriction?
Authors: William T McGivney
Journal: Journal of the National Comprehensive Cancer Network (2011)

weigh in all levels of decision making; however, the attraction of building businesses that can be developed and sold in short periods of time may enthrall and entice a few.It could also overwhelm the formal, evidence-based, systematic, and transparent processes that have been established on behalf of the patients we serve.Therefore, it is critical that clinicians understand fully the bases, sources, and implications of decision-making programs in which they might be "invited" to participate.
Colonoscopy quality indicators: from individual performance to institutional policy
Authors: Marek Bugajski, Michal Kaminski
Journal: Endoscopy (2015)

The quality of colonoscopy is considered key to the efficacy of the examination. The two most widely used quality indicators for colonoscopy – cecal intubation rate (CIR) and adenoma detection rate (ADR) – have been shown to be associated with interval colorectal cancer [1] [2] [3].
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
Authors: K Lindemann, G Kristensen, M R Mirza, L Davies, F Hilpert, I Romero, A Ayhan, A Burges, M J Rubio, F Raspagliesi, M Huizing, G-J Creemers, M Lykka, C K Lee, V Gebski, E Pujade-Lauraine
Journal: Annals of Oncology (2016)
Identification of Existing Bioactive Compounds That Target Acute Myeloid Leukemia Stem Cells
Authors: Isabelle Laverdiere, Andrea L. Neumann, Meaghan Boileau, Heather Duncan, Sara Chisling, Amanda Mithchell, Stanley W.K. Ng, Jean C.Y. Wang, Mark D. Minden, John E. Dick, Kolja Eppert
Journal: Blood (2015)
A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer
Authors: P. Neuhaus, H. Oettle, S. Post, K. Gellert, K. Ridwelski, H. Schramm, C. Zülke, G. Fahlke, J. Langrehr, H. Riess
Journal: Journal of Clinical Oncology (2005)

LBA4013 Background: Chemotherapy with Gemcitabine 1 g/m2 given on d 1, 8, 15 every four weeks is standard therapy in inoperable pancreatic cancer. The value of adjuvant therapy has not been clearly defined and no data on randomised trials with Gemcitabine in the adjuvant setting is available. Methods: This study was designed to evaluate the efficacy and toxicity of Gemcitabine in patients with resectable pancreatic cancer. Within 6 weeks after operation, patients were randomised to receive Gemcitabine or observation after stratification for positive or negative resection margins, nodal tumor involvement and tumor stage. Gemcitabine was administered at a dosage of 1g/m2 days 1, 8 and 15 every 4 weeks for 6 months. Patients in the observation arm received no specific postoperative treatment. Primary endpoint was disease free survival (DFS), secondary endpoints included overall survival (OS) and side effects in both groups. The study was powered to detect a significant difference with 90% probability at a significance level of 0.05. Results: Between 07/98 and 12/2004, 368 patients were randomised after a safety only interim analysis confirmed feasibility of adjuvant Gemcitabine therapy without excessive toxicity. At the meeting, data on time-to-event endpoints and toxicity data will be available and be presented. Conclusion: Will be made after final analysis of the results is completed. The results will be presented at the meeting. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Lilly Oncology Lilly Oncology
Case 44-1971
Authors: Richard C. Cabot, Benjamin Castleman, Betty U. McNeely, Walter H. Abelmann, Benjamin Castleman
Journal: New England Journal of Medicine (1971)

Presentation of CaseA five-year-old boy was admitted to the hospital because of left-sided chest pain.He was well until one week previously, when he was taken to a physician because of an upper-respiratory-tract infection. Examination disclosed a Grade 4 precordial systolic murmur. An electrocardiogram was interpreted as normal. An x-ray film of the chest (Fig. 1) showed cardiac enlargement; the lungs were clear, and the pulmonary vasculature was slightly congested. The urine was normal; the hematocrit was 33 per cent; the white-cell count was 18,800, with 84 per cent neutrophils. Measles vaccine was given. Five days later a cough . . .
Successfull Engraftment and Clearance of Donor Specific Antibodies after Haploidentical Related Stem Cell Transplantation for an Adult Patient with Sickle Cell Disease
Authors: Sabine FÜrst, Emmanuelle Bernit, Jean El Cheikh, Angela Granata, Samia Harbi, Bilal Mohty, Laurence Caymaris, Claude Lemarie, Boris Calmels, Christian Chabannon, Christophe Picard, Djamel Mokart, Borje Andersson, Didier Blaise
Journal: Blood (2014)
Phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.
Authors: D. Michaelson, D. F. McDermott, M. B. Atkins, D. C. Cho, K. M. Olivier, A. B. Schwarzberg, T. K. Choueiri
Journal: Journal of Clinical Oncology (2010)

e15076 Background: Sunitinib is a standard front-line treatment for metastatic renal cell carcinoma (mRCC) patients (pts), but is not proven to be beneficial in pts with poor-risk clinical features or sarcomatoid histology. These two populations of mRCC pts typically have short median survival. We are conducting a phase 2 study of combination treatment with sunitinib and gemcitabine in clinical or pathologic poor-risk mRCC. Methods: Eligible pts with mRCC have either elements of sarcomatoid histology or poor-risk disease by modified clinical criteria (3 or more of the following: ECOG PS > 1, time from diagnosis to treatment < 12 months, anemia, hypercalcemia, LDH ≥ 1.5 normal, or ≥ 2 sites of disease). Treatment consists of 21-day cycles of sunitinib 37.5 mg daily (2 weeks on, 1 week off), and gemcitabine 1000 mg/m2 on days 1 and 8. Pts may have received no more than one prior therapy for mRCC. A total of 36 pts will be enrolled, and the primary endpoint is radiographic response rate by RECIST. Secondary endpoints include progression free survival (PFS), safety and tolerability, and overall survival. Results: Twenty five pts have been treated to date. Of these, 13 were eligible due to sarcomatoid histology, and the remaining pts were eligible based on clinical poor-risk criteria. Among 20 patients evaluable for response, 5 had confirmed partial response (25%), including 3 with sarcomatoid histology, and an additional 10/20 exhibited stable disease for ≥ 12 weeks (50%). None of 5 pts with underlying papillary or chromophobe RCC histology has responded. Median PFS is 4.6 months among the patients with sarcomatoid RCC (range 2-12 months), 5.9 months among clinical poor- risk pts (range: 1-8 months), and 4.8 months overall. Five pts have been removed from study due to adverse events, including fatigue, hemolytic anemia, renal dysfunction, and cumulative grade 2 toxicities. Median overall survival has not been reached. Conclusions: Treatment of mRCC pts with sarcomatoid histology or clinical poor-risk features using a combination regimen of sunitinib and gemcitabine results in a clinical benefit rate of 75% and PFS of 4.8 months. Further prospective study of this regimen is warranted in these subpopulations of mRCC. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Abbott Laboratories, Aggenix, Antigenics, AVEO, Bayer, Genentech, GlaxoSmithKline, Novartis, Onyx, Pfizer, Roche, Wyeth Pfizer, Wyeth Amgen, Bayer, Genentech, Novartis, Pfizer
Glioblastoma (GBM) in elderly patients: A randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ).
Authors: A. Malmstrom, B. H. Grønberg, R. Stupp, C. Marosi, D. Frappaz, H. P. Schultz, M. U. Abacioglu, S. Kinhult, R. Henriksson
Journal: Journal of Clinical Oncology (2010)

LBA2002 Background: Despite treatment advances, survival of elderly GBM patients (pts) is usually &lt; 12 months. Hypofractionated RT is advocated in order to shorten treatment time, and chemotherapy has been proposed as an alternative to RT. In a randomized trial we compared two different RT schedules with single-agent TMZ chemotherapy. Methods: Newly diagnosed GBM pts age ≥ 60 years with PS 0-2, were randomized to either standard RT (60 Gy in 2 Gy fractions over 6 weeks) or hypofractionated RT (34 Gy in 3,4 Gy fractions over 2 weeks) or 6 cycles of chemotherapy with TMZ (200 mg/m 2 day 1-5 every 28 days). Follow-up including quality of life, symptom checklist, and steroid dosing was completed at 6 weeks, 3 months, and 6 months after start of treatment. The primary study end point was overall survival (OS). Results: A total of 342 pts were included. 291 pts were randomized between the 3 treatment options, 51 pts between hypofractionated RT and TMZ. Median age was 70 years (range 60-88), 59% were male and 72% had undergone tumor resection, the remaining 28% had a diagnostic biopsy only. Performance status was 0-1 for 75% of pts. Survival data are available for 334 pts (98%), with 11 pts (3%) being alive. There was no significant difference in OS between the three treatment arms, with median survival being 8 months for TMZ, 7.5 months for hypofractionated RT and 6 months for 6 weeks RT (p=0.14). Conclusions: Elderly patients with GBM have a short survival. Time-consuming therapy that does not offer longer survival should therefore be avoided. Our study showed no advantage of standard 6 weeks RT compared to hypofractionated RT over 2 weeks or 6 cycles of TMZ chemotherapy. These results indicate that standard RT should no longer be offered to the elderly pt population with GBM. Exclusive TMZ chemotherapy may be an alternative to RT. Subgroup analyses and determination of molecular markers is ongoing. Whether outcome could be improved by concomitant chemoradiotherapy is subject of ongoing clinical trials. [Table: see text]
Mental health and choice between managed care and indemnity health insurance
Authors: T V Perneger, A F Allaz, J F Etter, A Rougemont
Journal: American Journal of Psychiatry (1995)

Populations enrolled in various health insurance plans may differ in their health care needs. Whether mental health affects choice among competing health plans is not clear. This study examined self-selection by participants in a Swiss indemnity insurance plan that was transformed into a managed care organization that controlled access to specialists through gatekeeping and restricted coverage for psychiatric treatments.Information regarding past use of health services and health status was provided by 421 persons who joined the new managed care organization and 222 nonjoiners. The mental health and somatic health characteristics of these two groups were compared.In the year preceding the creation of the managed care organization, the nonjoiners had made on average 2.3 more visits to psychiatrists than the joiners but 0.0 to 0.6 more visits to other physicians. The nonjoiners were more likely to have used psychoactive medications but not other medications. The rates of treatment for depression were similar in the two groups. The joiners reported significantly lower mental health status, but not somatic health status, than the nonjoiners.Both mental health status and past use of mental health services strongly affected choice of health insurance plan. The effects of somatic health and use of somatic health services on selection were consistently weaker. People who join managed care organizations may have substantial uncovered needs for psychiatric care. Minimum mandatory benefits for mental health care may be an effective countermeasure to unequitable self-selection.
Isolated Right Ventricular Myocardial Infarction
Authors: David T. Harnett, Stephen A. LaHaye, Jeffrey S. Wilkinson
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal